Leerink Partners Downgrades Veracyte to Market Perform From Outperform
Leerink Partners lowered its rating on Veracyte to Market Perform from Outperform and set a $35 price target.
Leerink Partners lowered its rating on Veracyte to Market Perform from Outperform and set a $35 price target.